SCHEMBL2748907

SCHEMBL2748907

O=c1ccn(-c2ccc(C(F)(F)F)cc2)nc1-c1ccnn1-c1cccc(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 6/20 0.65
ALDH1A1 P00352 2/20 0.53
CASR P41180 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
KDM4E B2RXH2 2/20 0.44
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM1A O60341 1/20 0.41
UBE2N P61088 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL519292 0.92 PDE10A (0.65) PDE10AALDH1A1MEN1KMT2ACYP1A2
SCHEMBL2750293 0.89 PDE10A (0.72) PDE10AALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL3503870 0.88 PDE10A (0.58) PDE10AALDH1A1MEN1KMT2ACYP1A2
SCHEMBL3503982 0.88 PDE10A (0.68) PDE10AALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL519072 0.88 PDE10A (0.67) PDE10AALDH1A1CASRMEN1KMT2A
SCHEMBL2505485 0.88 PDE10A (0.70) PDE10AALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL2749209 0.88 PDE10A (0.77) PDE10AALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL2503685 0.87 PDE10A (0.72) PDE10AALDH1A1MEN1KMT2AKDM4E
SCHEMBL518752 0.87 PDE10A (0.63) PDE10AALDH1A1MEN1KMT2ACYP1A2
SCHEMBL2494448 0.86 PDE10A (0.66) PDE10AALDH1A1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373641-B1 PYRIDAZINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-12-19 EP claimed
US-8178538-B2 Pyridazinones HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US claimed
US-20100152193-A1 PYRIDAZINONES HOFFMANN-LA ROCHE, INC. 2010-06-17 US claimed
EP-2373641-B1 PYRIDAZINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-12-19 EP disclosed
US-8178538-B2 Pyridazinones HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
US-8178538-B2 Pyridazinones HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
US-8178538-B2 Pyridazinones HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
US-20100152193-A1 PYRIDAZINONES HOFFMANN-LA ROCHE, INC. 2010-06-17 US disclosed
US-20100152193-A1 PYRIDAZINONES HOFFMANN-LA ROCHE, INC. 2010-06-17 US disclosed
US-20100152193-A1 PYRIDAZINONES HOFFMANN-LA ROCHE, INC. 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152193-A1 PYRIDAZINONES PDE5A, PDE3A, PDE10A PDE10A 3/4885ALDH1A1 251/4885CASR 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.